...
首页> 外文期刊>Journal of Inorganic Biochemistry: An Interdisciplinary Journal >The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic,spectroscopic (IR, ES+ MS, NMR, 57Fe Mossbauer), theoretical, and biological activity studies
【24h】

The first iron(III) complexes with cyclin-dependent kinase inhibitors: Magnetic,spectroscopic (IR, ES+ MS, NMR, 57Fe Mossbauer), theoretical, and biological activity studies

机译:第一种具有细胞周期蛋白依赖性激酶抑制剂的铁(III)配合物:磁,光谱(IR,ES + MS,NMR,57Fe Mossbauer),理论和生物学活性研究

获取原文
获取原文并翻译 | 示例
           

摘要

The first FeIII complexes 1–6 with cyclin-dependent kinase (CDK) inhibitors of the type [Fe(Ln)Cl3]nH2O (n = 0 for 1, 1 for 2, 2 for 3–6; L1–L6 = C2- and phenyl-substituted CDK inhibitors derived from 6-benzylamino- 9-isopropylpurine), have been synthesized and characterized by elemental analysis, IR, 57Fe Mossbauer, 1H and 13C NMR, and ES+ mass spectroscopies, conductivity and magnetic susceptibility measurements, and thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). The study revealed that the compounds are mononuclear, tetrahedral high-spin (S = 5/2) FeIII complexes with an admixture of an S = 3/2 spin state originating probably from five-coordinated FeIII ions either connecting with a bidentate coordination mode of the CDK inhibitor ligand or relating to the possibility that one crystal water molecule enters the coordination sphere of the central atom in a portion of molecules of the appropriate complex. Nearly spin-only value of the effective magnetic moment (5.82 leff/lB) was determined for compound 1 due to absence of crystal water molecule(s) in the structure of the complex. Based on NMR data and DFT calculations, we assume that the appropriate organic ligand is coordinated to the FeIII ion through the N7 atom of a purine moiety. The cytotoxicity of the complexes was tested in vitro against selected human cancer cell lines (G-361, HOS, K-562 and MCF-7) along with the ability to inhibit the CDK2/cyclinE kinase. The best cytotoxicity (IC50: 4–23 lM) and inhibition activity (IC50: 0.02– 0.09 lM) results have been achieved in the case of complexes 2–4, and complexes 3, 4 and 6, respectively. In addition, the X-ray structure of 2-chloro-6-benzylamino-9-isopropylpurine, i.e. a precursor for the preparation of L1, L4 and L5, is also described.
机译:第一批FeIII与[Fe(Ln)Cl3] nH2O类型的细胞周期蛋白依赖性激酶(CDK)抑制剂1-6络合(n = 0表示1,1表示2,2表示3-6; L1-L6 = C2-合成并通过元素分析,IR,57Fe Mossbauer,1H和13C NMR,ES +质谱,电导率和磁化率测量以及热重分析来合成和表征由6-苄基氨基-9-异丙基嘌呤衍生的苯基取代的CDK抑制剂) (TGA)和差示扫描量热法(DSC)。研究表明,这些化合物是单核,四面体高自旋(S = 5/2)FeIII配合物,具有S = 3/2自旋态的混合物,可能源自五配位的FeIII离子,它们的双齿配位模式为CDK抑制剂配体,或与一个晶体水分子在适当配合物的一部分分子中进入中心原子的配位球有关。由于配合物结构中不存在结晶水分子,因此确定了化合物1的有效磁矩几乎只有自旋值(5.82 leff / lB)。根据NMR数据和DFT计算,我们假设适当的有机配体通过嘌呤部分的N7原子与FeIII离子配位。在体外针对选定的人类癌细胞系(G-361,HOS,K-562和MCF-7)测试了复合物的细胞毒性以及抑制CDK2 / cyclinE激酶的能力。复合物2-4,复合物3、4和6分别具有最佳的细胞毒性(IC50:4–23 lM)和抑制活性(IC50:0.02–0.09 lM)。另外,还描述了2-氯-6-苄氨基-9-异丙基嘌呤的X射线结构,即制备L1,L4和L5的前体。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号